Photo of A. Simon Pickard

A. Simon Pickard

Director of Graduate Studies, Pharmacy Systems, Outcomes and Policy
Professor, Pharmacy Systems, Outcomes and Policy
Assistant Director, Center for Pharmacoepidemiology and Pharmacoeconomic Research


Building & Room:

Room 254, College of Pharmacy


833 South Wood Street, Chicago, IL, 60612

Office Phone:

(312) 413-3357

Office Phone TTY:

(312) 996-2954


Dr. A. Simon Pickard is a Professor in the Department of Pharmacy Systems, Outcomes, and Policy (PSOP), and Assistant Director at the Center for Pharmacoepidemiology and Pharmacoeconomic Research. Dr. Pickard received his BS in Pharmacy and PhD from the University of Alberta. His research focuses on informing decision making in health care the evaluation of health outcomes, and pharmacy-related policy issues. He is internationally known for his work in the measurement and valuation of health-related quality of life, particularly the EQ-5D. He has received numerous research awards, including several from the International Society for Quality of Life Research. In addition to his active research program, he is currently the Director of Graduate Studies for PSOP.

Selected Publications

  • Devlin N, Brazier J, Pickard AS, Stolk E. (2018). “3L, 5L, What the L? A NICE Conundrum”. PharmacoEconomics. Vol. 36. Issue 6. Page(s) 637-640.
  • Pickard AS, Jalundhwala YJ, Bewsher H, Sharp L, Walton SM, Schumock GT, Caskey RN. “Lifestyle-related attitudes: do they explain self-rated health and life-satisfaction?”. Quality of Life Research. 2018;27(5):1227-1235. doi:10.1007/s11136-017-1774-3.
  • Zueger PM, Holmes HM, Calip GS, Qato D, Pickard AS, Lee TA. “Medicare Part D Use of Older Medicare Beneficiaries Admitted to Hospice”. Journal of the American Geriatrics Society. 2018;66(5):937-944. doi:10.1111/jgs.15328.
  • Samp JC, Joo MJ, Schumock GT, Calip GS, Pickard AS, Lee TA. “Predicting acute exacerbations in chronic obstructive pulmonary disease”. Journal of Managed Care and Specialty Pharmacy. 2018;24(3):265-279. doi:10.18553/jmcp.2018.24.3.265.
  • Schumock GT, Pickard AS. “Comparative effectiveness and patient-centered outcomes research: Enhancing uptake and use by patients, clinicians and payers”. Journal of Comparative Effectiveness Research. 2018;7(2):177-180. doi:10.2217/cer-2017-0057.
  • Devine EB, Perfetto E, Pickard AS, Schumock GT, Segal JB, Cannon E, Gagnon JP, Brixner DI, Garrison LP, Murray MD. (2018). “Nine years of comparative effectiveness research education and training: Initiative supported by the PhRMA Foundation”. Journal of Comparative Effectiveness Research. Vol. 7. Issue 2. Page(s) 167-175.
  • Xie F, Pullenayegum E, Pickard AS, Ramos Goñi JM, Jo MW, Igarashi A. “Transforming Latent Utilities to Health Utilities: East Does Not Meet West”. Health Economics (United Kingdom). 2017;26(12):1524-1533. doi:10.1002/hec.3444.
  • Krabbe PF, Stolk EA, Devlin NJ, Xie F, Quik EH, Pickard AS. “Head-to-head comparison of health-state values derived by a probabilistic choice model and scores on a visual analogue scale”. European Journal of Health Economics. 2017;18(8):967-977. doi:10.1007/s10198-016-0841-y.
  • Samp JC, Joo MJ, Schumock GT, Calip GS, Pickard AS, Lee TA. “Risk of Cardiovascular and Cerebrovascular Events in COPD Patients Treated With Long-Acting β2-Agonist Combined With a Long-Acting Muscarinic or Inhaled Corticosteroid”. Annals of Pharmacotherapy. 2017;51(11):945-953. doi:10.1177/1060028017719716.
  • Law EH, Pickard AL, Kaczynski A, Pickard AS. “Choice Blindness and Health-State Choices among Adolescents and Adults”. Medical Decision Making. 2017;37(6):680-687. doi:10.1177/0272989X17700847.
  • Norman R, Viney R, Aaronson NK, Brazier JE, Cella D, Costa DS, Fayers PM, Kemmler G, Peacock S, Pickard AS, Rowen D, Street DJ, Velikova G, Young TA, King MT. (2017). “Erratum to: Using a discrete choice experiment to value the QLU-C10D: feasibility and sensitivity to presentation format (Quality of Life Research, (2016), 25, 3, (637-649), 10.1007/s11136-015-1115-3)”. Quality of Life Research. Vol. 26. Issue 8. Page(s) 2247-2248.
  • Jiang R, Lee I, Lee TA, Pickard AS. “The societal cost of heroin use disorder in the United States”. PLoS ONE. 2017;12(5). doi:10.1371/journal.pone.0177323.
  • Samp JC, Joo MJ, Schumock GT, Calip GS, Pickard AS, Lee TA. “Comparative Effectiveness of Long-Acting Beta2-Agonist Combined with a Long-Acting Muscarinic Antagonist or Inhaled Corticosteroid in Chronic Obstructive Pulmonary Disease”. Pharmacotherapy. 2017;37(4):447-455. doi:10.1002/phar.1913.
  • Pickard AS, Gooderham M, Hartz S, Nicolay C. “EQ-5D health utilities: exploring ways to improve upon responsiveness in psoriasis”. Journal of Medical Economics. 2017;20(1):19-27. doi:10.1080/13696998.2016.1219359.
  • Norman R, Kemmler G, Viney R, Pickard AS, Gamper E, Holzner B, Nerich V, King M. “Order of Presentation of Dimensions Does Not Systematically Bias Utility Weights from a Discrete Choice Experiment”. Value in Health. 2016;19(8):1033-1038. doi:10.1016/j.jval.2016.07.003.
  • King MT, Costa DS, Aaronson NK, Brazier JE, Cella DF, Fayers PM, Grimison P, Janda M, Kemmler G, Norman R, Pickard AS, Rowen D, Velikova G, Young TA, Viney R. (2016). “Erratum to: QLU-C10D: a health state classification system for a multi-attribute utility measure based on the EORTC QLQ-C30 (Qual Life Res, (2016), 25, (625-636, 10.1007/s11136-015-1217-y))”. Quality of Life Research. Vol. 25. Issue 10. Page(s) 2683.
  • Norman R, Viney R, Aaronson NK, Brazier JE, Cella D, Costa DS, Fayers PM, Kemmler G, Peacock S, Pickard AS, Rowen D, Street DJ, Velikova G, Young TA, King MT. (2016). “Erratum to: Using a discrete choice experiment to value the QLU-C10D: feasibility and sensitivity to presentation format (Qual Life Res, (2016), 25, (637-649), 10.1007/s11136-015-1115-3)”. Quality of Life Research. Vol. 25. Issue 9. Page(s) 2401.
  • Melzer AC, Feemster LC, Crothers K, Carson SS, Gillespie SE, Henderson AG, Krishnan JA, Lindenauer PK, McBurnie MA, Mularski RA, Naureckas ET, Pickard AS, Au DH. “Respiratory and bronchitic symptoms predict intention to quit smoking among current smokers with, and at risk for, chronic obstructive pulmonary disease”. Annals of the American Thoracic Society. 2016;13(9):1490-1496. doi:10.1513/AnnalsATS.201601-075OC.
  • Pickard AS, Jiang R, Lin HW, Rosenbloom S, Cella D. “Using Patient-reported Outcomes to Compare Relative Burden of Cancer: EQ-5D and Functional Assessment of Cancer Therapy-General in Eleven Types of Cancer”. Clinical Therapeutics. 2016;38(4):769-777. doi:10.1016/j.clinthera.2016.03.009.
  • King MT, Costa DS, Aaronson NK, Brazier JE, Cella DF, Fayers PM, Grimison P, Janda M, Kemmler G, Norman R, Pickard AS, Rowen D, Velikova G, Young TA, Viney R. “QLU-C10D: a health state classification system for a multi-attribute utility measure based on the EORTC QLQ-C30”. Quality of Life Research. 2016;25(3):625-636. doi:10.1007/s11136-015-1217-y.
  • Norman R, Viney R, Aaronson NK, Brazier JE, Cella D, Costa DS, Fayers PM, Kemmler G, Peacock S, Pickard AS, Rowen D, Street DJ, Velikova G, Young TA, King MT. “Using a discrete choice experiment to value the QLU-C10D: feasibility and sensitivity to presentation format”. Quality of Life Research. 2016;25(3):637-649. doi:10.1007/s11136-015-1115-3.
  • Golicki D, Niewada M, Karlińska A, Buczek J, Kobayashi A, Janssen MF, Pickard AS. “Comparing responsiveness of the EQ-5D-5L, EQ-5D-3L and EQ VAS in stroke patients”. Quality of Life Research. 2015;24(6):1555-1563. doi:10.1007/s11136-014-0873-7.
  • Crawford SY, Okorie-Awe C, Tawk RH, Pickard AS. A cross sectional and longitudinal study of pharmacy student perceptions of readiness to serve diverse populations. American Journal of Pharmaceutical Education (in press). .
  • Cheng WH, Patel H, Lee WJ, Lin FJ, Pickard AS. “Positive Outcomes of Varicose Vein Surgery: The Patient Perspective”. Patient. 2015;8(4):329-337. doi:10.1007/s40271-014-0092-x.
  • Xie F, Pickard AS, Krabbe PF, Revicki D, Viney R, Devlin N, Feeny D. “A Checklist for Reporting Valuation Studies of Multi-Attribute Utility-Based Instruments (CREATE)”. PharmacoEconomics. 2015;33(8):867-877. doi:10.1007/s40273-015-0292-9.
  • Craig BM, Pickard AS, Rand-Hendriksen K. “Do health preferences contradict ordering of EQ-5D labels?”. Quality of Life Research. 2015;24(7):1759-1765. doi:10.1007/s11136-014-0897-z.
  • Golicki D, Niewada M, Buczek J, Karlińska A, Kobayashi A, Janssen MF, Pickard AS. “Validity of EQ-5D-5L in stroke”. Quality of Life Research. 2015;24(4):845-850. doi:10.1007/s11136-014-0834-1.
  • Pickard AS. (2015). “Is it Time to Update Societal Value Sets for Preference-Based Measures of Health?”. PharmacoEconomics. Vol. 33. Issue 3. Page(s) 191-192.
  • Jiang RM, Pickard EA, Lee TS, Pickard A. Emergence of BCR-ABL kinase domain mutations associated with newly diagnosed chronic myeloid leukemia: a meta-analysis of clinical trials of tyrosine kinase inhibitors.. Journal of managed care & specialty pharmacy. 2015;21(2):114-22.
  • Lee WJ, Lee TA, Pickard AS, Shoaibi A, Schumock GT. “Using linked electronic data to validate algorithms for health outcomes in administrative databases”. Journal of Comparative Effectiveness Research. 2015;4(4):359-366. doi:10.2217/cer.15.14.
  • Krabbe PF, Devlin NJ, Stolk EA, Shah KK, Oppe M, Van Hout B, Quik EH, Pickard AS, Xie F. “Multinational evidence of the applicability and robustness of discrete choice modeling for deriving EQ-5D-5L health-state values”. Medical Care. 2014;52(11):935-943. doi:10.1097/MLR.0000000000000178.
  • Lee WA, Lee TS, Pickard AN, Caskey RT, Schumock G. Drugs associated with adverse events in children and adolescents.. Pharmacotherapy. 2014;34(9):918-26. doi:10.1002/phar.1455.
  • Lin FJ, Pickard AS, Krishnan JA, Joo MJ, Au DH, Carson SS, Gillespie SG, Henderson AK, Lindenauer PA, McBurnie MA, Mularski RT, Naureckas EM, Vollmer WA, Lee T. Measuring health-related quality of life in chronic obstructive pulmonary disease: properties of the EQ-5D-5L and PROMIS-43 short form.. BMC medical research methodology. 2014;14:78. doi:10.1186/1471-2288-14-78.
  • Craig BM, Reeve BB, Cella D, Hays RD, Pickard AS, Revicki DA. “Demographic differences in health preferences in the United States”. Medical Care. 2014;52(4):307-313. doi:10.1097/MLR.0000000000000066.
  • Pickard AS, Kohlmann T, Janssen MF, Bonsel G, Rosenbloom S, Cella D. (2014). “Erratum: Evaluating equivalency between response systems: Application of the rasch model to a 3 level and 5 level EQ-5D (Medical Care (2014) 45:9 (812-819))”. Medical Care. Vol. 52. Issue 4. Page(s) 385.
  • Lin FJ, Samp J, Munoz A, Wong PS, Pickard AS. “Evaluating change using patient-reported outcome measures in knee replacement: The complementary nature of the EQ-5D index and VAS scores”. European Journal of Health Economics. 2014;15(5):489-496. doi:10.1007/s10198-013-0489-9.
  • Craig BM, Pickard AS, Lubetkin EI. “Health problems are more common, but less severe when measured using newer EQ-5D versions”. Journal of Clinical Epidemiology. 2014;67(1):93-99. doi:10.1016/j.jclinepi.2013.07.011.
  • Recht M, Neufeld EJ, Sharma VR, Solem CT, Pickard AS, Gut RZ, Cooper DL. “Impact of acute bleeding on daily activities of patients with congenital hemophilia with inhibitors and their caregivers and families: Observations from the dosing observational study in hemophilia (DOSE)”. Value in Health. 2014;17(6):744-748. doi:10.1016/j.jval.2014.07.003.
  • Golicki D, Niewada M, Hout Bv, Janssen MF, Pickard AS. “Interim EQ-5D-5L Value Set for Poland: First Crosswalk Value Set in Central and Eastern Europe”. Value in Health Regional Issues. 2014;4(1):19-23. doi:10.1016/j.vhri.2014.06.001.
  • Prieto-Centurion V, Markos MA, Ramey NI, Gussin HA, Nyenhuis SM, Joo MJ, Prasad B, Bracken N, DiDomenico RJ, Godwin PO, Jaffe HA, Kalhan R, Pickard AS, Pittendrigh BR, Schatz B, Sullivan JL, Thomashow BM, Williams MV, Krishnan JA. (2014). “Interventions to reduce rehospitalizations after chronic obstructive pulmonary disease exacerbations: A systematic review”. Annals of the American Thoracic Society. Vol. 11. Issue 3. Page(s) 417-424.
  • Patel HN, Ursan ID, Zueger PM, Cavallari LH, Pickard AS ed. “Stakeholder views on pharmacogenomic testing” . January (1st Quarter/Winter)-1-2014.
  • Lin FJ, Lee TA, Wong PS, Pickard AS. Evaluation of changes in guidelines for medication management of stable chronic obstructive pulmonary disease.. Journal of evaluation in clinical practice. 2013;19(5):953-60. doi:10.1111/j.1365-2753.2012.01892.x.
  • Janssen MF, Pickard AS, Golicki D, Gudex C, Niewada M, Scalone L, Swinburn P, Busschbach J. “Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L across eight patient groups: A multi-country study”. Quality of Life Research. 2013;22(7):1717-1727. doi:10.1007/s11136-012-0322-4.
  • Pickard AS, Tawk R, Shaw JW. “The effect of chronic conditions on stated preferences for health”. European Journal of Health Economics. 2013;14(4):697-702. doi:10.1007/s10198-012-0421-8.
  • Craig BM, Pickard AS, Stolk E, Brazier JE. “US valuation of the SF-6D”. Medical Decision Making. 2013;33(6):793-803. doi:10.1177/0272989X13482524.
  • Lin FJ, Longworth L, Pickard AS. “Evaluation of content on EQ-5D as compared to disease-specific utility measures”. Quality of Life Research. 2013;22(4):853-874. doi:10.1007/s11136-012-0207-6.
  • Craig BM, Hays RD, Pickard AS, Cella D, Revicki DA, Reeve BB. “Comparison of US panel vendors for online surveys.”. Journal of medical Internet research. 2013;15(11). doi:10.2196/jmir.2903.
  • Samp JC, Schumock GT, Pickard AS. Retracted publications in the drug literature.. Pharmacotherapy. 2012;32(7):586-95. doi:10.1002/j.1875-9114.2012.01100.x.
  • Solem CT, Lee TA, Joo MJ, Walton SM, Pickard AS. Complexity of medication use in newly diagnosed chronic obstructive pulmonary disease patients.. The American journal of geriatric pharmacotherapy. 2012;10(2):110-122.e1. doi:10.1016/j.amjopharm.2011.12.003.
  • Pickard AS, Lee TA, Solem CT, Joo MJ, Schumock GT, Krishnan JA. Prioritizing comparative-effectiveness research topics via stakeholder involvement: an application in COPD.. Clinical pharmacology and therapeutics. 2011;90(6):888-92. doi:10.1038/clpt.2011.237.
  • Liu FX, Alexander GC, Crawford SY, Pickard AS, Hedeker DM, Walton S. The impact of Medicare Part D on out-of-pocket costs for prescription drugs, medication utilization, health resource utilization, and preference-based health utility.. Health services research. 2011;46(4):1104-23. doi:10.1111/j.1475-6773.2011.01273.x.
  • Pickard AS, Yang YA, Lee T. Comparison of health-related quality of life measures in chronic obstructive pulmonary disease.. Health and quality of life outcomes. 2011;9:26. doi:10.1186/1477-7525-9-26.
  • Lin HW, Pickard AS, Mahady GB, Karabatsos GY, Crawford SG, Popovich N. An instrument to evaluate pharmacists’ patient counseling on herbal and dietary supplements.. American journal of pharmaceutical education. 2010;74(10):192.
  • Wilke CT, Pickard AS, Walton SM, Moock JA, Kohlmann T, Lee T. Statistical implications of utility weighted and equally weighted HRQL measures: an empirical study.. Health economics. 2010;19(1):101-10. doi:10.1002/hec.1467.
  • Pickard AS, Lin HW, Trask PC, Aaronson NA, Lee T, Cella D. A patient-based utility measure of health for clinical trials of cancer therapy based on the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire.. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. 2009;12(6):977-88. doi:10.1111/j.1524-4733.2009.00545.x.
  • Lee TA, Schumock GT, Bartle BS, Pickard A. Mortality risk in patients receiving drug regimens with theophylline for chronic obstructive pulmonary disease.. Pharmacotherapy. 2009;29(9):1039-53. doi:10.1592/phco.29.9.1039.
  • Lee TA, Wilke CT, Joo MA, Stroupe KT, Krishnan JS, Schumock G, Pickard A. Outcomes associated with tiotropium use in patients with chronic obstructive pulmonary disease.. Archives of internal medicine. 2009;169(15):1403-10. doi:10.1001/archinternmed.2009.233.
  • Schumock GT, Pickard AS. Comparative effectiveness research: Relevance and applications to pharmacy.. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 2009;66(14):1278-86. doi:10.2146/ajhp090150.
  • Jung ES, Pickard AW, Salmon JA, Bartle B, Lee T. Medication adherence and persistence in the last year of life in COPD patients.. Respiratory medicine. 2009;103(4):525-34. doi:10.1016/j.rmed.2008.11.004.
  • Pickard AS, Jung EB, Bartle BA, Weiss K, Lee T. Coded cause of death and timing of COPD diagnosis.. COPD. 2009;6(1):41-7. doi:10.1080/15412550802587935.
  • Lee TA, Pickard AS, Au DH, Bartle BB, Weiss K. Risk for death associated with medications for recently diagnosed chronic obstructive pulmonary disease.. Annals of internal medicine. 2008;149(6):380-90.
  • Lin HW, Pickard AS, Mahady GB, Popovich NG. Conceptual development of a measure to assess pharmacists’ knowledge of herbal and dietary supplements.. American journal of pharmaceutical education. 2008;72(3):59.
  • Pickard AS, Wilke CA, Jung E, Patel S, Stavem K, Lee T. Use of a preference-based measure of health (EQ-5D) in COPD and asthma.. Respiratory medicine. 2008;102(4):519-36. doi:10.1016/j.rmed.2007.11.016.
  • Pickard AS, Becker RC, Schumock GT, Frye CB. Clopidogrel-associated bleeding and related complications in patients undergoing coronary artery bypass grafting.. Pharmacotherapy. 2008;28(3):376-92. doi:10.1592/phco.28.3.376.
  • Lee TA, Pickard AS. Meta-analysis of azelastine nasal spray for the treatment of allergic rhinitis.. Pharmacotherapy. 2007;27(6):852-9. doi:10.1592/phco.27.6.852.
  • Lee TA, Pickard AS, Bartle BB, Weiss K. Osteoarthritis: a comorbid marker for longer life?. Annals of epidemiology. 2007;17(5):380-4. doi:10.1016/j.annepidem.2007.01.033.
  • McKoy JM, Lyons EA, Obadina ES, Carson KE, Pickard AT, Schellhammer PL, McLeod D, Boyd C, McWilliams N, Sartor O, Schumock G, McCaffery K, Bennett C. Caveat medicus: consequences of federal investigations of marketing activities of pharmaceutical suppliers of prostate cancer drugs.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005;23(34):8894-905. doi:10.1200/JCO.2005.01.4605.
  • Wolf MS, Fitzner KA, Powell EF, McCaffrey KR, Pickard AS, McKoy JM, Lindenberg JT, Schumock GR, Carson KR, Ferreira MC, Dolan NL, Bennett C. Costs and cost effectiveness of a health care provider-directed intervention to promote colorectal cancer screening among Veterans.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005;23(34):8877-83. doi:10.1200/JCO.2005.02.6278.
  • Pickard AS, Hung SY, McKoy JM, Witt WP, Arseven AJ, Sharifi RT, Wu ZL, Knight S, McWilliams N, Schumock G, Bennett C. Opportunities for disease state management in prostate cancer.. Disease management : DM. 2005;8(4):235-44. doi:10.1089/dis.2005.8.235.
  • Pickard AS, Wang Z, Walton SM, Lee TA. Are decisions using cost-utility analyses robust to choice of SF-36/SF-12 preference-based algorithm?. Health and quality of life outcomes. 2005;3:11. doi:10.1186/1477-7525-3-11.
  • Pickard AS, Nau DP, McKercher PL, Schumock GT. Importation of prescription medications: experiences, opinions, and intended behaviors of U.S. community pharmacists.. Journal of the American Pharmacists Association : JAPhA. 2004;44(6):666-72.
  • Nutescu EA, Pickard AS, Blackburn JC, Wittkowsky AK, Ansell JT, Schumock G. Impact of oral direct thrombin inhibitors on anticoagulation clinics.. Pharmacotherapy. 2004;24(9):1204-12.
  • Park HY, Schumock GT, Pickard AS, Akhras K. A structured review of the relationship between microalbuminuria and cardiovascular events in patients with diabetes mellitus and hypertension.. Pharmacotherapy. 2003;23(12):1611-6.
  • Pickard AS, Schumock GT. (2002). Aspirin use may change cost-effectiveness of COX-2 inhibitors.. Archives of internal medicine. Vol. 162. Issue 22. Page(s) 2637-8; author reply 2638-9.